Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide once-weekly for multiple system atrophy
2020-000122-26Phase 2Unknown
- Sponsor
- University College London
- Start
- Apr 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exenatide in multiple system atrophy (MSA) (2 arms), sponsored by University College London. Primary endpoint: Change in total UMSARS score at 48 weeks. Status: unknown.
02
Drugs
exenatide
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2020-000122-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000122-26.